Perpetual Observational Study - Ventilator Associated Pneumonia
Key facts
- Who runs it
- European Clinical Research Alliance for Infectious Diseases (ECRAID)
- Where
- Albania, Belgium, Croatia, Czechia, France, Germany, Greece, Italy, Netherlands, Romania, Serbia, Spain, and United Kingdom35 sites in 13 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 7,844 people enrolled
- Started
- 3 Aug 2022
- Expected to end
- 1 Mar 2027
- Type of study
- Observational, 3 groups
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age≥18 years
- At risk of acquiring VAP during ICU stay, defined as:
- Requiring admission or being admitted to the ICU
- Expected or documented to be under IMV for more than 48 hours
- Consent, either a written informed consent given by the study patient in full medical, psychological, cognitive, social or legal capacity to give an informed consent, or, if not possible, by a Legally Authorized Representative of the study patient OR any applicable locally accepted form of consent OR consent waiver allowing data collection and sharing of data according to ECRAID's principles
Who cannot take part
- Death is deemed to be imminent or inevitable during this hospital admission AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
This trial has no sites in United States.
It has sites in 13 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation. It is linked to higher chances of death, a longer stay in the hospital, higher costs, and the use of more antibiotics.
Read full original descriptionShow less
Options to help prevent or treat this disease are in development and will require evaluation in future clinical trials.
The goal of POS-VAP is to build and continuously train a network of ICUs to be prepared for doing these trials, to facilitate their execution.
The 3 groups in the trial
- Enrolled population
All patients meeting eligibility criteria (Adult patients, under a documented or expected time under mechanical ventilation of at least \>48h) and providing one of: * Informed consent * Hospital level consent * Non-objection notice * Waiver of consent
- VAP population
Subset of the enrolled population fulfilling U.S. Food and Drug Administration (FDA) criteria for VAP diagnosis at any time during the follow up
- Microbiologically evaluable VAP population
Subset of the VAP population with a documented causative agent (bronchoalveolar lavage \[BAL\], endotracheal aspirate \[ETA\], blood sample, sputum, or pleural fluid) within 48 hours from VAP diagnosis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- POS-VAP: Perpetual Observational Study - Ventilator Associated Pneumonia
- Record updated
- 12 November 2026